Our News
2024 Year in Review & Look Ahead: CEO Yvonne Greenstreet Highlights a Pivotal Year for Alnylam
March 25, 2025
Dr. Yvonne Greenstreet
Chief Executive Officer, Alnylam Pharmaceuticals
2024 was a pivotal year for Alnylam, defined by strong commercial growth and outstanding progress within our pipeline and highlighted by the overwhelmingly positive data from the landmark HELIOS-B study of vutrisiran for patients with ATTR amyloidosis with cardiomyopathy.
The HELIOS-B study met all ten of its primary and secondary endpoints and demonstrated an extraordinary impact in reducing mortality and improving quality of life. Vutrisiran has the potential to become a first-line therapy and the new standard of care for the treatment of ATTR cardiomyopathy. We are thrilled with what these results mean for patients, physicians, families, and caregivers.
The results from this study marked a transformational moment for Alnylam, and the anticipated launch of vutrisiran in a large and expanding market holds the potential to drive a new era of unprecedented growth for the company.
In 2024, Alnylam emerged as a top-tier biotechnology company, with a flagship franchise, a pipeline humming with promise, a strong financial foundation, and a vibrant culture. Ahead of us lies the opportunity to transform the lives of millions of patients.
I'm pleased to note some highlights from last year that underscore the strong progress we made across our business below and invite you to read more in our 2024 annual report [Link].
Strong commercial execution: Our commercial execution was strong last year. We generated $1.6 billion in combined net product revenues, at the upper end of our revised financial guidance and 33% greater than in 2023. This exemplary performance was driven by growing demand overall within our portfolio of products — AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran) — serving patients in more than 70 countries. Sales of Leqvio® (inclisiran), an Alnylam-discovered RNAi-therapeutic marketed throughout the world by Novartis, more than doubled.
Our revenue has increased at a compound annual growth rate of 59% since 2019—the initial full year following the launch of our first product—and we believe we are well positioned for continued exceptional growth over the long term.
We ended 2024 with a cash and investment balance of approximately $2.7 billion and achieved non-GAAP operating income profitability for the first time, a major milestone for the company. Sustaining profitability moving forward will allow us to fund the substantial investment in R&D needed to realize the enormous promise within our pipeline, deliver groundbreaking medicines for patients, and increase the value of the company.
A pipeline humming with promise: We made equally strong progress last year in advancing potentially transformative medicines and expect to have more than 25 programs in clinical development by the end of 2025.
- Detailed findings from the HELIOS-B study were presented at the European Society of Cardiology Congress (ESC), one of the world’s largest meetings of cardiologists, and published simultaneously in The New England Journal of Medicine (NEJM). This was Alnylam’s 13th NEJM publication, a remarkable record that further underscores our pioneering science and medical innovation.
- With the HELIOS-B results in hand, we moved with urgency to bring vutrisiran to patients around the world, submitting regulatory applications in the U.S., EU, Japan, and other markets, with additional filings to follow in 2025.
- Our ambition to establish Alnylam as the leader in ATTR amyloidosis is reflected in our continued investment in potential new treatment options for patients beyond vutrisiran. We reported interim positive results from a Phase 1 study of our next-generation product candidate in development for the treatment of ATTR amyloidosis, nucresiran (ALN-TTRsc04), which delivered profound TTR lowering with biannual dosing. We plan to begin pivotal studies in both ATTR cardiomyopathy and polyneuropathy in 2025.
Growth through innovation: Our mid-stage pipeline features groundbreaking opportunities for transformational medicines poised to make a profound impact on human health.
- We made important progress with zilebesiran for people with hypertension, reporting positive results from the KARDIA-2 Phase 2 study showing significant additive blood pressure lowering in combination with additional standard-of-care hypertensive medicines. We plan to begin a cardiovascular outcomes trial this year.
- Similarly, we reported positive initial results from the multiple dose portion of the Phase 1 study of mivelsiran in early onset Alzheimer’s disease, initiated a Phase 2 study of mivelsiran in cerebral amyloid angiopathy, and began a Phase 1 study of ALN-HTT02, bringing hope to patients with Huntington’s disease.
- We expanded our pipeline with four proprietary Clinical Trial Applications and applications by our collaboration partners. We also advanced exciting efforts to deliver RNAi therapeutics to new tissues, which will allow us to broaden the range of diseases we seek to treat.
Our people and culture: As we grow, we continue to build a culture that inspires, supports, and attracts passionate people who are eager to take on the challenges inherent in developing important new medicines. Alnylam was widely recognized again last year as an exceptional workplace by numerous organizations, including USA Today, Science Magazine, The Boston Globe, and LinkedIn. We also earned certification as a Great Place to Work® in 11 countries and ranked among Fortune’s best workplaces for parents and millennials.
Our responsibility: Finally, we were featured on Newsweek’s list of America’s Most Responsible Companies for the third year in a row, and maintained an ‘A’ Environmental, Social, and Governance rating with MSCI. In our annual Corporate Responsibility Report, we outlined our strong commitment to enabling access to our medicines, engaging in our communities, promoting health equity, and mitigating our environmental impact.
Four years ago, with the launch of our P5x25 strategy, we sought to establish Alnylam among the foremost biotechnology companies. Now we are focused on our next chapter. RNAi therapeutics hold the power to amplify life by silencing disease. The moment in front of us is more promising than any before and the opportunities more extraordinary. For Alnylam, we believe the best is yet to come.
